Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
2.41B | 2.36B | 1.89B | 1.49B | 1.13B | 1.05B | Gross Profit |
2.37B | 2.32B | 1.85B | 1.47B | 1.12B | 1.04B | EBIT |
497.30M | 570.50M | 250.90M | 249.00M | 196.90M | 318.90M | EBITDA |
539.80M | 639.70M | 358.00M | 264.60M | 218.70M | 336.10M | Net Income Common Stockholders |
305.80M | 341.30M | 249.70M | 154.50M | 89.60M | 407.30M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
460.48M | 1.08B | 1.03B | 989.30M | 711.30M | 801.00M | Total Assets |
806.36M | 3.72B | 3.25B | 2.37B | 2.07B | 1.73B | Total Debt |
374.21M | 455.10M | 428.40M | 262.90M | 440.40M | 412.30M | Net Debt |
198.90M | 222.10M | 177.30M | 0.00 | 99.60M | -388.70M | Total Liabilities |
441.87M | 1.13B | 1.02B | 660.90M | 698.50M | 608.50M | Stockholders Equity |
364.49M | 2.59B | 2.23B | 1.71B | 1.37B | 1.13B |
Cash Flow | Free Cash Flow | ||||
492.20M | 557.20M | 361.60M | 322.90M | 233.10M | 217.60M | Operating Cash Flow |
529.90M | 595.40M | 389.90M | 339.40M | 256.50M | 228.50M | Investing Cash Flow |
-57.60M | -126.80M | -467.10M | -177.10M | -130.20M | 4.10M | Financing Cash Flow |
-674.50M | -486.70M | 65.30M | -234.30M | 27.40M | -157.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $11.72B | 17.35 | 18.36% | 0.58% | 13.26% | 1.33% | |
74 Outperform | $11.92B | 39.63 | 12.43% | ― | 21.73% | -19.24% | |
63 Neutral | $3.71B | ― | -3.64% | 4.14% | -4.85% | -4290.31% | |
63 Neutral | $14.05B | ― | -8.58% | ― | 46.62% | 50.50% | |
59 Neutral | $20.47B | ― | -18.98% | ― | 3.38% | -175.90% | |
52 Neutral | $5.22B | 3.55 | -44.39% | 2.82% | 15.40% | -0.09% | |
52 Neutral | $10.52B | ― | -21.25% | 5.36% | -6.88% | -6809.78% |
Neurocrine Biosciences announced the appointment of Dr. Sanjay Keswani as Chief Medical Officer effective June 2, 2025, succeeding Dr. Eiry W. Roberts, who will remain as a strategic advisor. Dr. Keswani brings over 20 years of pharmaceutical industry experience and will lead clinical development and medical affairs, enhancing the company’s capabilities as it explores new therapeutic modalities.